713 related articles for article (PubMed ID: 29285777)
1. Analogous detection of circulating tumor cells using the AccuCyte
van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free Method.
Chalfin HJ; Kates M; van der Toom EE; Glavaris S; Verdone JE; Hahn NM; Pienta KJ; Bivalacqua TJ; Gorin MA
Urology; 2018 May; 115():82-86. PubMed ID: 29432873
[TBL] [Abstract][Full Text] [Related]
3. Nucleolin Staining May Aid in the Identification of Circulating Prostate Cancer Cells.
Chalfin HJ; Verdone JE; van der Toom EE; Glavaris S; Gorin MA; Pienta KJ
Clin Genitourin Cancer; 2017 Jun; 15(3):e477-e481. PubMed ID: 28153390
[TBL] [Abstract][Full Text] [Related]
4. The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
Dong L; Zhang Z; Smith K; Kuczler MD; Reyes D; Amend SR; Cho YK; Xue W; Pienta KJ
BJU Int; 2020 Jul; 126(1):191-201. PubMed ID: 32115854
[TBL] [Abstract][Full Text] [Related]
5. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining.
Campton DE; Ramirez AB; Nordberg JJ; Drovetto N; Clein AC; Varshavskaya P; Friemel BH; Quarre S; Breman A; Dorschner M; Blau S; Blau CA; Sabath DE; Stilwell JL; Kaldjian EP
BMC Cancer; 2015 May; 15():360. PubMed ID: 25944336
[TBL] [Abstract][Full Text] [Related]
6. RareCyte
Werbin JL; Nordberg JJ; Tzucker J; Varshavskaya P; Stilwell JL; Kaldjian EP
Methods Mol Biol; 2017; 1634():173-180. PubMed ID: 28819850
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types.
Takagi H; Dong L; Kuczler MD; Lombardo K; Hirai M; Amend SR; Pienta KJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261132
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
[TBL] [Abstract][Full Text] [Related]
10. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of a novel one-stop ISET device to capture CTCs and its clinical application.
Chen F; Wang S; Fang Y; Zheng L; Zhi X; Cheng B; Chen Y; Zhang C; Shi D; Song H; Cai C; Zhou P; Xiong B
Oncotarget; 2017 Jan; 8(2):3029-3041. PubMed ID: 27935872
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer.
Dirix L; Buys A; Oeyen S; Peeters D; Liègeois V; Prové A; Rondas D; Vervoort L; Mariën V; Laere SV; Vermeulen P
Breast Cancer Res Treat; 2022 Jun; 193(2):437-444. PubMed ID: 35397078
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.
Krebs MG; Hou JM; Sloane R; Lancashire L; Priest L; Nonaka D; Ward TH; Backen A; Clack G; Hughes A; Ranson M; Blackhall FH; Dive C
J Thorac Oncol; 2012 Feb; 7(2):306-15. PubMed ID: 22173704
[TBL] [Abstract][Full Text] [Related]
14. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
[No Abstract] [Full Text] [Related]
15. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
[TBL] [Abstract][Full Text] [Related]
16. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
17. Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.
Yeo D; Kao S; Gupta R; Wahlroos S; Bastian A; Strauss H; Klemm V; Shrestha P; Ramirez AB; Costandy L; Huston R; Gardner BS; Grimison P; Clark JR; Rasko JEJ
Front Oncol; 2023; 13():1141228. PubMed ID: 37051527
[TBL] [Abstract][Full Text] [Related]
18. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.
Hofman V; Ilie MI; Long E; Selva E; Bonnetaud C; Molina T; Vénissac N; Mouroux J; Vielh P; Hofman P
Int J Cancer; 2011 Oct; 129(7):1651-60. PubMed ID: 21128227
[TBL] [Abstract][Full Text] [Related]
19. RareCyte® CTC Analysis Step 1: AccuCyte® Sample Preparation for the Comprehensive Recovery of Nucleated Cells from Whole Blood.
Ramirez AB; U'Ren L; Campton DE; Stewart D; Nordberg JJ; Stilwell JL; Kaldjian EP
Methods Mol Biol; 2017; 1634():163-172. PubMed ID: 28819849
[TBL] [Abstract][Full Text] [Related]
20. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
